Barclays
LUCD icon

Barclays’s Lucid Diagnostics LUCD Stock Holding History

Barclays’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.9K Sell
16,453
-124,714
-88% -$159K ﹤0.01% 4587
2025
Q4 		$154K Buy
141,167
+40,891
+41% +$45.7K ﹤0.01% 4439
2025
Q3 		$101K Sell
100,276
-19,726
-16% -$21.5K ﹤0.01% 4612
2025
Q2 		$138K Buy
120,002
+118,418
+7,476% +$153K ﹤0.01% 4491
2025
Q1 		$2.36K Buy
+1,584
New +$1.9K ﹤0.01% 4984
2022
Q2 		– Sell
-822
Closed -$2K – 5164
2022
Q1 		$2K Buy
+822
New +$3K ﹤0.01% 4787

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Barclays's LUCD Position: Q1 2026 in Review

Barclays reduced its Lucid Diagnostics (LUCD) stake by 88% in Q1 2026, selling an estimated $159K and leaving 16,453 shares worth $18.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4587.

Barclays first reported a position in LUCD in Q1 2022 and has held it in 6 quarters since. The position peaked at $154K in Q4 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Barclays held 16,453 shares of Lucid Diagnostics worth $18.9K as of Q1 2026.
  • Barclays sold 124,714 Lucid Diagnostics shares in Q1 2026, an estimated $159K.
  • Lucid Diagnostics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4587 holding.
  • Barclays first reported a position in Lucid Diagnostics in Q1 2022 and has held it in 6 quarters since.
  • Barclays's Lucid Diagnostics position peaked at $154K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.